Holen Sie sich die Stockscreener-App
5.2998
0.54%
-0.0202
Schlusskurs vom Vortag:
$5.32
Offen:
$5.35
24-Stunden-Volumen:
289.83K
Relative Volume:
0.27
Marktkapitalisierung:
$283.48M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-57.44M
KGV:
-3.9666
EPS:
-1.3361
Netto-Cashflow:
$-56.46M
1W Leistung:
-10.31%
1M Leistung:
-18.72%
6M Leistung:
+68.52%
1J Leistung:
+31.63%
1-Tages-Spanne:
$5.24
$5.49
1-Wochen-Bereich:
$5.21
$6.07
52-Wochen-Spanne:
$2.77
$7.82
Protara Therapeutics Inc Stock (TARA) Company Profile
Firmenname
Protara Therapeutics Inc
Sektor
Branche
Telefon
646-844-0337
Adresse
345 PARK AVENUE SOUTH, NEW YORK, NY
Compare TARA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
5.29 | 285.08M | 0 | -57.44M | -56.46M | -1.3361 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.70 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.79 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
705.66 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.82 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.42 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-04 | Eingeleitet | JP Morgan | Overweight |
| 2026-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2025-04-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-03-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-10 | Fortgesetzt | Guggenheim | Buy |
| 2021-06-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-02-17 | Eingeleitet | Oppenheimer | Outperform |
| 2020-10-19 | Eingeleitet | Cowen | Outperform |
| 2020-07-29 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Protara Therapeutics Inc Aktie (TARA) Neueste Nachrichten
FY2030 Earnings Forecast for TARA Issued By HC Wainwright - MarketBeat
Published on: 2026-03-12 04:53:12 - baoquankhu1.vn
Cowen Maintains Buy on Protara Therapeutics (TARA) March 10, 2026 - Meyka
TD Cowen reiterates Protara Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
TARA Advances Clinical Programs with Key Milestones Ahead - GuruFocus
TARA Secures Financial Stability with $197.9 Million Cash Reserves - GuruFocus
Protara Therapeutics (NASDAQ:TARA) Releases Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
Protara Therapeutics (NASDAQ: TARA) advances TARA-002 and IV Choline into registrational-stage trials - Stock Titan
Protara Therapeutics 2025 Annual Report: Pipeline, Regulatory Strategy, and Commercialization Plans for Cancer and Rare Disease Therapies - Minichart
Protara 10-K: Net loss $57.4M, EPS $(1.34); operating loss widens to $64.5M - TradingView
Protara Therapeutics reports $197.9M cash; Q4 net loss $17.3M, FY loss $57.4M - TradingView
Protara Therapeutics: Q4 Earnings Snapshot - Barchart.com
TARA: TARA-002 achieved high response rates in NMIBC, with cash runway into 2028 after a major offering - TradingView
Bladder cancer drug hits 68% response; Protara sees cash runway into 2028 - Stock Titan
Geopolitics Watch: What is the Moat Score of Protara Therapeutics IncWeekly Trend Recap & Verified Momentum Stock Alerts - baoquankhu1.vn
Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Millennium Management LLC Acquires Significant Stake in Protara Therapeutics Inc - GuruFocus
Protara gains as JP Morgan starts at overweight - Seeking Alpha
Protara Therapeutics (NASDAQ:TARA) Now Covered by JPMorgan Chase & Co. - MarketBeat
JP Morgan Initiates Coverage on TARA with Overweight Rating and $27 PT | TARA Stock News - GuruFocus
Breakout Watch: Can Protara Therapeutics Inc beat the S P 5002025 Sector Review & Weekly High Return Opportunities - baoquankhu1.vn
Millennium group reports 2.76M shares in Protara (TARA) — 5.1% stake - Stock Titan
Protara Therapeutics Highlights TARA-002 NMIBC Data, FDA Plans for Lymphatic Malformations at Oppenheimer Conf - Yahoo Finance
TARA PE Ratio & Valuation, Is TARA Overvalued - Intellectia AI
TARA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Protara Therapeutics Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
TARA Should I Buy - Intellectia AI
Protara Therapeutics, Inc. (TARA) Presents at 2026 ASCO Genitourinary Cancers SymposiumSlideshow - Seeking Alpha
TARA: TARA-002 advances in NMIBC and LM with promising data and expanding regulatory pathways - TradingView
667, L.P. resale reported for TARA (NASDAQ: TARA) — 26,755 shares - Stock Titan
Protara Therapeutics (TARA) Receives a Buy from Piper Sandler - The Globe and Mail
ASCO-GU 2026: Key Oncology Updates From VIR, TARA, TYRA And Others - RTTNews
Protara Therapeutics (TARA) to Release Earnings on Wednesday - MarketBeat
Protara Therapeutics Highlights Phase 2 TARA-002 Data in NMIBC, Cites Strong Response Rates at ASCO GU - MarketBeat
Protara Therapeutics (TARA) Shares Drop 22% After Interim Trial Data - GuruFocus
[144] Protara Therapeutics, Inc. SEC Filing - Stock Titan
Protara reports interim results from bladder cancer trial By Investing.com - Investing.com South Africa
Protara falls after trial data for lead asset (TARA:NASDAQ) - Seeking Alpha
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Bladder phase II sinks Protara, LMs phase III wins for Palvella - BioWorld MedTech
Protara Highlights Strong Phase 2 Data for TARA-002 - TipRanks
TARA: TARA-002 shows strong efficacy and safety in NMIBC, with high CR rates and durable responses - TradingView
Protara posts positive interim ADVANCED-2 results; TARA-002 shows 68% 6‑month CR in BCG‑unresponsive NMIBC - TradingView
What's Going On With Protara Therapeutics Stock Tuesday?Protara Therapeutics (NASDAQ:TARA) - Benzinga
TARA-002 results send Protara shares upwards - The Pharma Letter
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Does TARA Stock’s 15% After-Hours Slump Signal A Bargain After New Bladder Cancer Data? - Stocktwits
Protara Therapeutics stock tumbles on trial data release By Investing.com - Investing.com South Africa
Protara Therapeutics (TARA) Shares Promising Phase 2 Trial Resul - GuruFocus
Protara Therapeutics stock tumbles on trial data release - Investing.com
Protara Therapeutics (TARA) Shares Promising Phase 2 Trial Results - GuruFocus
Finanzdaten der Protara Therapeutics Inc-Aktie (TARA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):